Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Philadelphia Chromosome 1

Interventions

Carboplatin 27pembrolizumab 26Cisplatin 24Paclitaxel 21Nivolumab 19Gemcitabine 16Pemetrexed 14Rituximab 14Ipilimumab 12Cyclophosphamide 11Dexamethasone 11Fluorouracil 10Capecitabine 9Docetaxel 9durvalumab 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5Ado-Trastuzumab Emtansine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × nilotinib × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

Novartis

Phase 2 Completed
215 enrolled 7 charts 1 FDA
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

Novartis

Phase 2 Completed
163 enrolled 7 charts 1 FDA
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡